Alzheimer’s latest drug and science journalism’s memory problem

In July, the medical community was rocked by a disappointing reminder of science’s weakest link: the humans doing the work. The journal Science had shared that its six-month investigation supported the findings of whistleblower Matthew Schrag, who first noted altered images in a high-impact paper on Alzheimer’s, published in Nature in 2006. That paper is still flagged on Nature as under review, but the damage has already been done. Alzheimer’s drugs for the last decade and a half have been developed around claims without as much evidence as initially believed—which might also explain why they haven’t been working, leading people to pour false hope into useless and often expensive treatment plans for declining loved ones.

Alzheimer’s latest drug and science journalism’s memory problem

Medicare officials say costly Alzheimer’s drug to blame for large monthly jump in premium

Medicare officials say costly Alzheimer’s drug to blame for large monthly jump in premium

The increase guarantees that health care will gobble up a big chunk of the recently announced Social Security cost-of-living allowance, a boost that had worked out to $92 a month for the average retired worker, intended to help cover rising prices for gas and food that are pinching seniors.

Related:

Biogen probes death of Aduhelm user after brain swelling

Cost and controversy are limiting use of new Alzheimer’s drug

How an Unproven Alzheimer’s Drug Got Approved